Investor Relations

Analyst Coverage
Jonathan Aschoff, Ph.D.
Phone: (646) 616-2795
H.C. Wainwright & Co., LLC
Vernon T. Bernardino
Phone: 646-975-6954
Zacks Investment Research, Inc.
John Vandermosten, CFA
Phone: 312-265-9558

View Analysis
Tenax Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Tenax Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tenax Therapeutics or its management. Tenax Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Tenax Therapeutics

A Phase 3, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.